Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Fresenius Kabi Files EU Pegfilgrastim

‘Milestone’ Biosimilar Submission Comes Ahead Of Planned Launch In 2021

May 26 2020

• By David Wallace

Fresenius Kabi — Fresenius Kabi has seen its biosimilar pegfilgrastim filing accepted for EMA review • Source: Shutterstock

Related Content

Fresenius Nod In EU Adds To Crowded Adalimumab Market

Feb 08 2019

Who’s Hired? Former Actavis Chief Bisaro Lands A New Role

Mar 26 2020

Emerging Markets Help Fresenius Kabi Offset US Pressures

Feb 28 2020

Fresenius Kabi Braced For ‘Pyrrhic Victory’ In Akorn Damages Lawsuit

May 07 2020

Related Companies

Fresenius SE & Co. KGaA

Additional Topics

Europe Biosimilars Regulation BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.